Skadden is representing Endo Pharmaceuticals in its $1.2 billion acquisition of Qualitest Pharmaceuticals, a leading, privately held generics company. The deal was announced on Sept. 28.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates